# IBT1116

Source: https://onco.cc/drugs/ibt1116/  
OnCo record `ibt1116` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IBT1116 is an experimental off-the-shelf immune cell treatment from ImmuneBro Therapeutics for B-cell cancers, including after CAR-T relapse. It has not yet entered trials.

## Summary

IBT1116 is the lead asset of ImmuneBro Therapeutics, an allogeneic engager T cell product at the IND-enabling stage for relapsed or refractory B-cell malignancies and relapse after CD19 CAR-T therapy, according to the company's website. No clinical data exist.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-04
- Tags: pipeline
- Code: IBT1116
- Modality: Allogeneic engager T cell therapy
- Mechanism: Healthy-donor T cells that also deliver a T cell engager, so they kill cancer cells directly and recruit the patient's own immune cells, without gene editing, as the developer describes.

## Sources

- ImmuneBro Therapeutics: https://www.immunebro.com/

## Connected records

- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/)
- companies: [ImmuneBro Therapeutics](https://onco.cc/companies/immunebro-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/ibt1116.json